Skip to main content
Equibles

Gary Stetz

CEO

Hepion Pharmaceuticals, Inc. (HEPA)

CFO

Hepion Pharmaceuticals, Inc. (HEPA)

Board Member

Hepion Pharmaceuticals, Inc. (HEPA)

Equibles does not estimate personal net worth.

Get an email with a short summary when Hepion Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.

Get HEPA alerts

About Gary Stetz

Gary Stetz is recorded as CFO at Hepion Pharmaceuticals, Inc. (HEPA) since October 9, 2026, Board Member at Hepion Pharmaceuticals, Inc. (HEPA) since March 16, 2026 and CEO at Hepion Pharmaceuticals, Inc. (HEPA). The newest filing on record that lists Gary Stetz as CEO at Hepion Pharmaceuticals, Inc. (HEPA) is dated April 28, 2026. Gary Stetz was last confirmed as Board Member at Canton Strategic Holdings, Inc. (CNTN) in a filing dated April 30, 2025. Hepion Pharmaceuticals, Inc. reported in an 8-K filed October 9, 2026 that Gary Stetz was appointed Chief Financial Officer, effective October 9, 2026. Hepion Pharmaceuticals, Inc. reported in an 8-K filed March 18, 2026 that Gary Stetz was appointed director, effective March 16, 2026. Hepion Pharmaceuticals, Inc. reported in an 8-K filed March 18, 2026 that Gary Stetz was appointed interim Chief Executive Officer, effective March 16, 2026. Equibles holds 4 filed executive changes naming Gary Stetz; each is listed under recent activity with its source filing. Hepion Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Hepion Pharmaceuticals, Inc. includes Dr. Kaouthar Lbiati (CEO), John Cavan (CEO and CFO), Kaouthar Lbiati (CEO and Board Member) and 7 others.

“On October 9, 2026, the board of directors (the “Board”) of the Company appointed Gary Stetz, the Company’s former Interim Chief Executive Officer, to serve as the Company’s Chief Financial Officer, and Sireesh Appajosyula, PharmD, the former Chief Executive Officer of Gravitas Life Sciences, LLC, to serve as the Company’s Chief Executive Officer, in each case effective as of October 9, 2026.”
Hepion Pharmaceuticals, Inc. Form 8-K, filed October 9, 2026 · Read the filing
“On March 16, 2026, the Board approved the appointment of Gary Stetz as interim Chief Executive Officer of the Company and director and appointed Vincent LoPriore as Executive Chairman, Sireesh Appajosyula as director and Chase LoPriore as director.”
Hepion Pharmaceuticals, Inc. Form 8-K, filed March 18, 2026 · Read the filing

Affiliation history

Company network

Leadership on record at Hepion Pharmaceuticals, Inc.

Recent activity